A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
Study sponsor: Kodiak Sciences Inc · KOD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-08-03Actual
Enrollment · participants253Actual
Source updated2024-09-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.